Colorectal cancer (CRC) screening, the decade's most promising cancer-related public health development, is evolving. Faecal immunochemical tests (FIT) will be the primary population-based CRC screening biomarker for the next 10–15 years. Will the international community exploit the full potential of FIT and other CRC risk indicators to enable a revolution in the effectiveness of screening?
- Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am. J. Gastroenterol. Gut 109, 1257–1264 (2014). et al.
- Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59, 62–68 (2010). et al.
- Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 62, 409–415 (2013). et al.
- Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut http://dx.doi.org/10.1136/gutjnl-2013-306144. et al.
- Challenges and possible solutions to colorectal cancer screening for the underserved. J. Natl Cancer Inst. 106, dju032 (2014). et al.
- Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366, 697–706 (2012). et al.
- Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol. J. 1, 198–205 (2013). et al.
- Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br. J. Cancer 100, 259–265 (2009). et al.
- Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol. Biomarkers Prev. 20, 272–280 (2011). et al.
- Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet 12, 551–558 (2011). et al.